Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dz13 DNAzyme
- Development stage
- Discontinued
- Lead developer
- NewSouth Innovations
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intratumoral
01
Overview
Dz13 DNAzyme is an experimental nucleic acid-based therapeutic developed by researchers at the University of New South Wales. It is a synthetic, single-stranded 10-23 DNAzyme designed to target and catalytically cleave the messenger RNA (mRNA) of c-Jun, a transcription factor critical for cell proliferation, angiogenesis, and inflammation. By inhibiting c-Jun expression, Dz13 aims to treat various conditions, including basal cell carcinoma, melanoma, and inflammatory diseases like arthritis. Clinical development, including a Phase I/Ib trial for melanoma metastases, was halted in 2013 following research misconduct allegations, although the lead investigator was subsequently cleared.
- Other names
- c-Jun DNAzyme
02
Targets
JUN (Transcription factor Jun)PARP1 (Poly (adp-ribose) polymerase 1)
Beyond the preview
Go deeper on Dz13 DNAzyme.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Dz13 DNAzyme.